Spillover adherence effects of fixed-dose combination HIV therapy

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 155-164

  Kauf, Teresa L ^a   Davis, Keith L ^b   Earnshaw, Stephanie R ^b   Anne Davis, E ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c NONE

Author keywords

Adherence; Antiretroviral; Fixed dose combination

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS STAVUDINE; ABACAVIR PLUS TENOFOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; DIDANOSINE PLUS LAMIVUDINE; DIDANOSINE PLUS TENOFOVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENDER; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICATION POSSESSION RATIO; MENTAL HEALTH; PATIENT COMPLIANCE; SENSITIVITY ANALYSIS; STATISTICAL CONCEPTS; SUBSTANCE ABUSE;

EID: 84880611713     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S28482     Document Type: Article

References (29)

1. Mocroft A, Ledergerber B, Katlama C; EuroSIDA study group, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22-29.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
3. Stone VE, Hogan JW, Schuman P; HERS study, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 2001;28(2):124-131.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011;1-167. Available from: http://www.aidsinfo.nih.gov/Content-Files/AdultandAdolescentGL.pdf. Accessed on October 31, 2011.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
6. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23(4):360-361.
7. Eron J Jr, Yeni P, Gathe J Jr; KLEAN study team, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368(9534):476-482.
8. Legorreta A, Yu A, Chernicoff H, Gilmore A, Jordan J, Rosenzweig JC. Adherence to combined lamivudine zidovudine versus individual components: a community-based retrospective medicaid claims analysis. AIDS Care. 2005;17(8):938-948.
9. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
10. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr. 2005;40(3): 294-300.
11. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1):158-163.
12. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to oncedaily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6(3):185-190.
13. Crémieux AC, Katlama C, Gillotin C; AZl10002 Study Group et al. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. Pharmacotherapy. 2001;21(4):424-430.
14. Lamarca A, Clumeck N, Plettenberg A, et al. Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). J Acquir Immune Defic Syndr. 2006;41(5):598-606.
15. Moore KH, Shaw S, Laurent AL, et al. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol. 1999;39(6):593-605.
16. Ingenix. Integrated Health Care Information Services. Available from: http://www.ingenix.com/AboutUs/Businesses/ihcis/.
17. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574.
18. Finkelstein E, Bray J, Larson M, et al. Mental health. In: Manderscheid RW, Henderson MJ, editors. Prevalence of, and payments for, mental health and substance abuse disorders in public and private sector health plans. Rockville, Maryland: United States Department of Health and Human Services, Center for Mental Health Services; 2002. Available from: http://store.samhsa.gov/product/Mental-Health-United-States-2002/SMA04-3938. Accessed on June 19, 2009.
19. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24(3):460-467.
20. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther. 2004;26(12):2066-2075.
21. Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ. Switching from twice-daily abacavir and lamivudine to the oncedaily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med. 2008;9(8):667-672.
22. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20(2):223-231.
23. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis. 2005;191(12):2046-2052.
24. White HD. Adherence and outcomes: it's more than taking the pills. Lancet. 2005;366(9502):1989-1991.
25. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2006. Available from: http://www.cdc.gov/hiv/surveillance/ resources/reports/2006report/. Accessed on January 23, 2009.
26. Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology. 2008;5:13.
27. Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008;22(4):301-312.
28. Martin M, Del Cacho CE, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24(10):1263-1268.
29. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother. 2009;43(3):413-422.